Fractyl Health (NASDAQ:GUTS) Stock Price Down 1.1%

Fractyl Health, Inc. (NASDAQ:GUTS)’s share price dropped 1.1% during trading on Thursday . The stock traded as low as $6.51 and last traded at $6.57. Approximately 69,309 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 383,212 shares. The stock had previously closed at $6.64.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on GUTS. Bank of America began coverage on Fractyl Health in a report on Tuesday, February 27th. They issued a “buy” rating and a $26.00 target price for the company. Evercore ISI began coverage on Fractyl Health in a report on Wednesday, February 28th. They issued an “outperform” rating for the company. Finally, Morgan Stanley began coverage on Fractyl Health in a report on Tuesday, February 27th. They issued an “overweight” rating and a $18.00 target price for the company.

Fractyl Health Stock Down 0.3 %

The stock has a 50-day moving average of $7.67.

Insider Buying and Selling

In other Fractyl Health news, Director Ajay Royan purchased 333,333 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $4,999,995.00. Following the transaction, the director now directly owns 1,251,900 shares in the company, valued at $18,778,500. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.